1335-P: Insulin-Sensitive and Resistant Endotypes in Persons With and Without Recent-Onset Diabetes and Their Association with Diabetes-Related Outcomes

Introduction Roche Pharma AG, BayerHealthCare. S. Meyhoefer: None. A.L. Birkenfeld: None. R. Jumpertz von Schwartzenberg: None. J. Seissler: None. A.F. Pfeiffer: Advisory Panel; Abbott. Speaker's Bureau; AstraZeneca, Novo Nordisk, Sanofi. Advisory Panel; Berlin-Chemie AG. M. Blüher: Speaker's Bureau; Amgen Inc., AstraZeneca, Bayer Inc., Daiichi Sankyo. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Speaker's Bureau; Pfizer Inc., Sanofi. S.R. Bornstein: None. Z. Kender: None. A. Sulaj: None. M. Heni: Research Support; Boehringer-Ingelheim. Advisory Panel; Amryt Pharma Plc. Speaker's Bureau; Amryt Pharma Plc. Advisory Panel; Boehringer-Ingelheim, Boehringer-Ingelheim. Speaker's Bureau; Lilly Diabetes, Novartis AG, Novo Nordisk, Sanofi. J. Szendroedi: None. M. Roden: Advisory Panel; Eli Lilly and Company. Research Support; Boehringer-Ingelheim. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; TARGET PharmaSolutions, Inc. Speaker's Bureau; AstraZeneca. R. Wagner: Speaker's Bureau; Sanofi. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Boehringer-Ingelheim, Novo Nordisk. Funding German Federal Ministry Berlin Germany of Health (BMG); Ministry of Culture and Science of the state North Rhine-Westphalia (MKW, Düsseldorf, Germany); German Federal Ministry of Education and Research (BMBF, Berlin, Germany); German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (236177352-SFB 1116) Schmutzler Stiftung; European Funds for Regional Development (EFRE-0400191)EUREKA Eurostars-2 (E! 113230 DIA-PEP)